1,131
Participants
Start Date
December 2, 2020
Primary Completion Date
April 7, 2021
Study Completion Date
July 25, 2022
AZD7442
Single dose (× 2 IM injections) of 300 mg of AZD7442 on Day 1.
Placebo
Single dose (× 2 IM injections) of saline placebo on Day 1.
Research Site, Bethesda
Research Site, Alexandria
Research Site, Richmond
Research Site, Portsmouth
Research Site, High Point
Research Site, Wilmington
Research Site, Orangeburg
Research Site, Conyers
Research Site, Atlanta
Research Site, Buford
Research Site, Mt. Dora
Research Site, Miami Lakes
Research Site, Miami Lakes
Research Site, Pembroke Pines
Research Site, Pompano Beach
Research Site, Coral Springs
Research Site, Miami
Research Site, Coral Gables
Research Site, Miami
Research Site, North Miami
Research Site, Miami Springs
Research Site, Miami
Research Site, Miami
Research Site, West Palm Beach
Research Site, Tampa
Research Site, Guntersville
Research Site, Owensboro
Research Site, Noblesville
Research Site, West Des Moines
Research Site, Chicago
Research Site, Chicago
Research Site, Wichita
Research Site, Little Rock
Research Site, Dallas
Research Site, Houston
Research Site, Friendswood
Research Site, San Antonio
Research Site, Harlingen
Research Site, Gonzales
Research Site, El Paso
Research Site, Riverton
Research Site, Tempe
Research Site, Huntington Park
Research Site, Huntington Beach
Research Site, Garden Grove
Research Site, Corona
Research Site, Bakersfield
Research Site, Modesto
Research Site, Tacoma
Research Site, Hazel Crest
Research Site, Bournemouth
Research Site, Hayle
Research Site, London
Research Site, London
Research Site, London
Research Site, Manchester
Research Site, Southampton
Lead Sponsor
Iqvia Pty Ltd
INDUSTRY
AstraZeneca
INDUSTRY